Nasopharyngitis ( 44 [ 11 % ] patients receiving benralizumab vs 13 [ 6 % ] patients receiving placebo ) and injection site reactions ( 60 [ 16 % ] vs eight [ 4 % ] ) occurred more frequently with benralizumab than with placebo .